GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OSTO:ABLI) » Definitions » EV-to-FCF

Abliva AB (OSTO:ABLI) EV-to-FCF : -19.72 (As of May. 24, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Abliva AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Abliva AB's Enterprise Value is kr179.29 Mil. Abliva AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was kr-9.09 Mil. Therefore, Abliva AB's EV-to-FCF for today is -19.72.

The historical rank and industry rank for Abliva AB's EV-to-FCF or its related term are showing as below:

OSTO:ABLI' s EV-to-FCF Range Over the Past 10 Years
Min: -43.42   Med: -1.47   Max: 0.05
Current: -23.01

During the past 13 years, the highest EV-to-FCF of Abliva AB was 0.05. The lowest was -43.42. And the median was -1.47.

OSTO:ABLI's EV-to-FCF is ranked worse than
100% of 367 companies
in the Biotechnology industry
Industry Median: 9.77 vs OSTO:ABLI: -23.01

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), Abliva AB's stock price is kr0.1756. Abliva AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.090. Therefore, Abliva AB's PE Ratio for today is At Loss.


Abliva AB EV-to-FCF Historical Data

The historical data trend for Abliva AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB EV-to-FCF Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.54 -2.39 -1.90 -0.76 -22.18

Abliva AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 -1.31 -1.40 -12.88 -22.18

Competitive Comparison of Abliva AB's EV-to-FCF

For the Biotechnology subindustry, Abliva AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abliva AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Abliva AB's EV-to-FCF falls into.



Abliva AB EV-to-FCF Calculation

Abliva AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=179.288/-9.092
=-19.72

Abliva AB's current Enterprise Value is kr179.29 Mil.
Abliva AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-9.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abliva AB  (OSTO:ABLI) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Abliva AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.1756/-0.090
=At Loss

Abliva AB's share price for today is kr0.1756.
Abliva AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.090.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Abliva AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Abliva AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Abliva AB (OSTO:ABLI) Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.

Abliva AB (OSTO:ABLI) Headlines

No Headlines